Bottle Label 100 mg (71610 0465 30)
Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-465
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena Pharma Solutions (TN)
Figure-1 (Losartan Fig1)
This appears to be a chart or table showing the results of a study on patients with primary endpoints who were treated with either Atenolol or Losartan Potassium. The chart shows an adjusted risk reduction of 13% for the latter drug, with a p-value of 0.021. The x-axis appears to show the timeline of the study in months.*
Figure-2 (Losartan Fig2)
This text shows the percentage of patients who had a fatal/non-fatal stroke while taking Atenolol or Losartan Potassium. The adjusted risk reduction for Losartan Potassium was 25%, with a p-value of 0.001. The chart also displays the study month timeline for up to 66 months.*
Figure-3 (Losartan Fig3)
Figure-4 (Losartan Fig4)
Structure (Losartan Struct)
Table-2 (Losartan Table2)
This is a table showing pharmacokinetic parameters in hypertensive adults and children between the ages of 6 and 16, following multiple dosing of 50 mg once daily for adults and 0.7 mg/kg once daily for children. The table displays the number of participants in each group, as well as various pharmacokinetic parameters such as the parent active metabolite and AUC (area under the curve). Additionally, mean, harmonic mean, and median values are provided for certain parameters.*
Table-3 (Losartan Table3)
This is a tabular data showing the incidence of primary endpoint events with Losartan and Potassium Atenolol. The primary composite endpoint, components of the primary composite endpoint, and the rate per 1000 patient-years of follow-up are listed. The text seems to be a result of a clinical trial.*
Table-4 (Losartan Table4)
Table-5 (Losartan Table5)
Table 5 shows the efficacy results for different demographic subgroups based on a study comparing the use of Rosils, Losartan, and placebo. The primary endpoint, event rate, hazard ratio, and confidence interval are reported for each subgroup. The subgroups analyzed include age, race, and ethnicity. The study found significant differences in outcomes between some subgroups, with Rosils and Losartan showing improved efficacy compared to placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
